COVID-19 Impacts: Antiviral Drugs Market Will Accelerate at a CAGR of Over 9% Through 2020–2024 | Growing Cases of Viral Infections to Boost Growth | Technavio
Technavio has been monitoring the antiviral drugs market and it is poised to grow by USD 43.37 billion during 2020–2024, progressing at a CAGR of over 9% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.
Frequently Asked Questions-Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Please Request Free Sample Report on COVID-19 Impact
- What was the value of the antiviral drugs market in 2019?
- Technavio says that the value of the market was at USD 76.00 billion in 2019 and it is projected to reach USD 128.09 billion by 2024.
- At what rate is the market projected to grow during the forecast period 2020–2024?
- Growing at a CAGR of over 9%, the market growth will accelerate in the forecast period of 2020–2024.
- What is the key factor driving the market?
- Growing cases of viral infections and the technological advancements are the key factors driving the market growth.
- Who are the top players in the market?
- AbbVie Inc., Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co. Inc., Novartis AG, Pfizer Inc., and Sanofi are some of the major market participants.
- Which region is expected to hold the highest market share?
- North America
- What is the year-over-year growth rate of the global market?
- The year-over-year growth rate for 2020 is estimated at 9.36%.
The market is fragmented, and the degree of fragmentation will accelerate during the forecast period. AbbVie Inc., Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co. Inc., Novartis AG, Pfizer Inc., and Sanofi are some of the major market participants. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
Growing cases of viral infections have been instrumental in driving the growth of the market.
Antiviral Drugs Market 2020–2024: Segmentation
Antiviral Drugs Market is segmented as below:
- Application
- Hepatitis
- HIV
- Herpes
- Influenza
- Others
- Geographic Landscape
- Asia
- Europe
- North America
- ROW
- MOA
- Reverse Transcriptase Inhibitors
- Protease Inhibitors
- Entry/fusion Inhibitors
- Immune System Modulators
- Others
To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR43207
Antiviral Drugs Market 2020–2024: Scope
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. Our antiviral drugs market report covers the following areas:
- Antiviral Drugs Market size
- Antiviral Drugs Market trends
- Antiviral Drugs Market analysis
This study identifies technological advancements as one of the prime reasons driving the antiviral drugs market growth during the next few years.
Antiviral Drugs Market 2020–2024: Vendor Analysis
We provide a detailed analysis of vendors operating in the antiviral drugs market, including some of the vendors such as AbbVie Inc., Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co. Inc., Novartis AG, Pfizer Inc., and Sanofi. Backed with competitive intelligence and benchmarking, our research reports on the antiviral drugs market are designed to provide entry support, customer profile and M&As as well as go-to-market strategy support.
